The Globe and Mail reports in its Tuesday, April 16, edition that Echelon Partners analyst Amr Ezzat has reaffirmed his "buy" recommendation for Sylogist. The Globe's David Leeder writes in the Eye On Equities column that Mr. Ezzat gave his share target a $1.50 boost to $12.50. Analysts on average target the shares at $12.21. Mr. Ezzat says recent investor meetings with Sylogist "further solidified" his positive outlook for Sylogist, emphasizing his "conviction in its strategic direction, market positioning and the effectiveness of its leadership team in executing its growth strategy." Mr. Ezzat says in a note: "The resurgence in growth is not a transient phenomenon but a well-orchestrated outcome of strategic decisions, particularly under the leadership of a revitalized management team and board. ... Significant investments in sales and marketing, as well as research and development, have enabled Sylogist's products to leapfrog those of its competitors and have laid a solid foundation for continued growth. ... Sylogist has shifted gears, leaving behind its old modus operandi of a 'Steady Eddie' operator with outsized margins, to one seeking to capitalize on growth more aggressively."